1. Bateman ED, Hurd SS, Barnes PJ et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008; 31: 143–78.
2. Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004; 59: 469–78.
3. Weiss KB, Sullivan SD, Lyttle CS. Trends in the cost of illness for asthma in the United States, 1985–1994. J Allergy Clin Immunol 2000; 106: 493–9.
4. Asthma insight and management. 2009. Available at: http://www.takingaimatasthma. com/survey-results.html. Accessed March 9, 2010.
5. Fuhlbrigge AL, Adams RJ, Guilbert TW et al. The burden of asthma in the United States: level and distribution are dependent on interpretation of the national asthma education and prevention program guidelines. Am J Respir Crit Care Med 2002; 166: 1044–9.
6. Global Initiative for Asthma. Global strategy for asthma management and prevention. Available from: www.ginasthma.org. Date last updated, 2009.
7. Gibson PG, Powell H, Ducharme FM. Differential effects of maintenance long-acting beta-agonist and inhaled corticosteroid on asthma control and asthma exacerbations. J Allergy Clin Immunol 2007; 119: 344–50.
8. Lai CK, De Guia TS, Kim YY et al. Asthma control in the Asia-Pacific region: the Asthma Insights and Reality in Asia-Pacific Study. J Allergy Clin Immunol 2003; 111: 263–8.
9. Rabe KF, Vermeire PA, Soriano JB, Maier WC. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J 2000; 16: 802–7.
10. Bateman ED, Boushey HA, Bousquet J et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004; 170: 836–44.
11. Barnes PJ. Using a combination inhaler (budesonide/formoterol) as rescue medication improves asthma control. BMJ 2007; 335: 513.
12. Scicchitano R, Aalbers R, Ukena D et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin 2004; 20: 1403–18.
13. O’Byrne PM, Bisgaard H, Godard P, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005; 171: 129–36.
14. Vogelmeier C, D’Urzo A, Pauwels R et al. Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option? Eur Respir J 2005; 26: 819–28.
15. Rabe KF, Atienza T, Magyar P et al. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet 2006; 368: 744–53.
16. Kuna P, Peters MJ, Manjra AI et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract 2007; 61: 725–36.
17. Bousquet J, Boulet LP, Peters MJ, et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs high-dose salmeterol/fluticasone. Respir Med 2007; 101: 2437–46.
18. Bateman ED, Reddel HK, Ericksson G et al. Overall asthma control: the relationship between current control and future risk. J Allergy Clin Immunol 2010; 125: 600–8.
19. Agarwal R, Khan A, Aggarwal AN, Gupta D. Is the SMART approach better than other treatment approaches for prevention of asthma exacerbations? A meta-analysis. Monaldi Arch Chest Dis 2009; 71: 161–9.
20. Edwards SJ, Gruffydd-Jones K, Ryan DP. Systematic review and meta-analysis of budesonide/formoterol in a single inhaler. Curr Med Res Opin 2007; 23: 1809–20.
21. Chapman KR. SMART isn’t. J Allergy Clin Immunol 2010; 125: 609–10.
22. Reddel HK, Taylor DR, Bateman ED et al. An official American Thoracic Society/European Respiratory Society Statement: asthma control and exacerbations standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009; 180: 59–99.
23. Asthma in America: a landmark survey. GlaxoSmithKline, 1998. Available at: http://www.asthmainamerica.com.
24. Kuehni CE, Frey U. Age-related differences in perceived asthma control in childhood: guidelines and reality. Eur Respir 
J 2002; 20: 880–9.
25. Juniper EF, O’Byrne PM, Guyatt GH et al. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999; 14: 902–7.
26. Nathan RA, Sorkness CA, Kosinski M et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol 2004; 113: 59–65.
27. Vollmer WM, Markson LE, O’Connor E et al. Association of asthma control with health care utilization and quality of life. Am J Respir Crit Care Med 1999; 160: 1647–52.
28. Boulet L-P, Boulet V, Milot J. How should we quantify asthma control? A proposal. Chest 2002; 122: 2217–23.
29. Juniper EF, O’Byrne PM, Roberts JN. Measuring asthma control in group studies: do we need airway calibre and rescue b2-agonist use? Respir Med 2001; 95: 319–23.
30. Svensson K, Mork AC, Juniper EF. ACQ – is five out of seven items acceptable in large clinical studies? Qual Life Res 2003; 12: 771.
31. Juniper EF, Svensson K, Mork AC et al. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med 2005; 99: 553–8.
32. Juniper EF, Bousquet J, Abetz L et al. Identifying ‘‘well-controlled’’ and ‘‘not well-controlled’’ asthma using the Asthma Control Questionnaire. Respir Med 2006; 100: 616–21.
33. Demoly P, Louis R, Søes-Petersen U et al. Budesonide/formoterol maintenance and reliever therapy versus conventional best practice. Respir Med 2009; 103: 1623–32.
34. McIvor RA, Pizzichini E, Turner MO et al. Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med 1998; 158: 924–30.
35. A multicenter, randomised, double-blind, parallel group study of the efficacy of fluticasone propionate (FP) diskus 100 mcg/bid or 500 mcg/bid to induce variations of eosinophils and of Eosinophil Cationic Protein (ECP) in serum and in sputum and to induce variations of exhaling nitric oxide (NO) in subjects with mild to moderate asthma Study No.: FLIC15. Data on file: www.gsk-clinicalstudyregister.com
36. Sears MR, Boulet L-P, Laviolette M et al. Budesonide/formoterol maintenance and reliever therapy: impact on airway inflammation in asthma. Eur Respir J 2008; 31: 982–9.
⁠

С.Н.Авдеев

ФГУ НИИ пульмонологии ФМБА России, Москва